1st patient dosed in trial for first in class drug PTX-100
Filed with ASX · · 4 pages · English
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Receipt of R&D Tax Rebate
- Prescient Ausbiotech Ras Presentation
- September 2019 Appendix 4C - Quarterly
- Appendix 4E and 2019 Annual Report
- June 2019 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- PTX in new CAR-T collaboration
- Third complete response in PTX-200 AML Trial
- Encouraging data from PTX-200 ovarian cancer trial
- PTX-200 High Overall Response in Ph2a Breast Cancer trial
- December 2019 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics